BioMarin Secures $850M in Senior Notes, Finalizes $2.8B Debt Facilities for Amicus Acquisition
Event summary
- BioMarin priced $850M of 5.500% senior unsecured notes due 2034, closing expected February 12, 2026.
- Completed syndication of $2B term loan B facility, adding to $800M term loan A and $600M revolving credit facility for Amicus acquisition.
- Total debt facilities amount to $3.6B to fund acquisition and related expenses.
- Notes are jointly guaranteed by BioMarin subsidiaries and will include customary restrictive covenants.
- Proceeds held in escrow; notes redeemable if acquisition fails by December 19, 2026.
The big picture
BioMarin's $3.6B debt financing package underscores its aggressive strategy to acquire Amicus, expanding its rare disease portfolio. The move reflects broader consolidation trends in biotech as companies seek scale to support high-cost drug development. The restrictive covenants on the notes will limit BioMarin's financial maneuverability, raising questions about its ability to pursue additional acquisitions or investments in its pipeline.
What we're watching
- Execution Risk
- Whether BioMarin can successfully close the Amicus acquisition by December 19, 2026, avoiding mandatory redemption of the notes.
- Debt Management
- How BioMarin will manage the increased debt load from the $3.6B in financing facilities while maintaining financial flexibility.
- Integration Challenges
- The pace at which BioMarin can integrate Amicus's operations and realize expected synergies from the acquisition.
Related topics